NPI 1710950720: Open Payments
NPI 1710950720. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,623 in 67 payments from 11 companies in 2025. Trend: 2023 $2,573 · 2024 $2,204 · 2025 $1,623
Food & beverage: $1,623
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $314 |
| E.R. Squibb & Sons, L.L.C. | 13 | $305 |
| Axsome Therapeutics, Inc. | 6 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $219 |
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| Vanda Pharmaceuticals Inc. | 5 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| Neurocrine BioSciences, Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
Products named: INVEGA SUSTENNA, COBENFY, Auvelity, TRINTELLIX, FANAPT, CAPLYTA, INGREZZA, UZEDY.
